(SRPT) Sarepta Therapeutics - Ratings and Ratios
RNA Therapeutics, Duchenne Muscular Dystrophy, Gene Therapy, Rare Diseases
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 92.9% |
| Value at Risk 5%th | 100% |
| Relative Tail Risk | -34.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.06 |
| Alpha | -105.51 |
| CAGR/Max DD | -0.48 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.433 |
| Beta | 1.483 |
| Beta Downside | 1.503 |
| Drawdowns 3y | |
|---|---|
| Max DD | 92.72% |
| Mean DD | 38.18% |
| Median DD | 25.70% |
Description: SRPT Sarepta Therapeutics November 13, 2025
Sarepta Therapeutics (NASDAQ:SRPT) is a commercial-stage biopharma that specializes in RNA-targeted and gene-therapy approaches for ultra-rare neuromuscular disorders, principally Duchenne muscular dystrophy (DMD).
Its approved portfolio includes EXONDYS 51, VYONDYS 53, and AMONDYS 45-exon-skipping antisense oligonucleotides that restore dystrophin production in mutation-specific DMD sub-populations-and ELEVIDYS, an AAV-based gene therapy for ambulatory pediatric DMD patients.
The pipeline extends beyond DMD with SRP-9003, a gene-therapy candidate for limb-girdle muscular dystrophy, and a suite of collaborative programs with partners such as Roche, Arrowhead, Dyno Therapeutics, and academic institutions.
Key recent metrics (Q4 2023) show total revenue of $258 million, driven largely by EXONDYS 51 sales, a net loss of $115 million, and cash & cash equivalents of $1.2 billion, giving the company roughly 18 months of runway at current burn rates.
Sector-wide forces that materially affect Sarepta’s outlook include escalating pricing power for one-time gene therapies (average US list price > $2 billion), expanding payer frameworks for rare-disease treatments, and the FDA’s accelerated approval pathways that can shorten time-to-market for novel exon-skipping agents.
For a deeper, data-driven valuation of SRPT’s risk-adjusted upside, you may find the analytical tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-271.5m TTM) > 0 and > 6% of Revenue (6% = 144.8m TTM) |
| FCFTA -0.11 (>2.0%) and ΔFCFTA 2.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 74.61% (prev 121.1%; Δ -46.45pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.07 (>3.0%) and CFO -244.6m > Net Income -271.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.95 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (100.2m) change vs 12m ago -0.21% (target <= -2.0% for YES) |
| Gross Margin 76.25% (prev 85.92%; Δ -9.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 68.06% (prev 45.57%; Δ 22.49pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -10.58 (EBITDA TTM -180.7m / Interest Expense TTM 21.8m) >= 6 (WARN >= 3) |
Altman Z'' -3.63
| (A) 0.52 = (Total Current Assets 2.72b - Total Current Liabilities 921.4m) / Total Assets 3.49b |
| (B) -1.33 = Retained Earnings (Balance) -4.64b / Total Assets 3.49b |
| warn (B) unusual magnitude: -1.33 — check mapping/units |
| (C) -0.06 = EBIT TTM -230.4m / Avg Total Assets 3.55b |
| (D) -2.14 = Book Value of Equity -4.64b / Total Liabilities 2.17b |
| Total Rating: -3.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 30.36
| 1. Piotroski 2.0pt |
| 2. FCF Yield -14.73% |
| 3. FCF Margin -16.01% |
| 4. Debt/Equity 0.95 |
| 5. Debt/Ebitda -3.53 |
| 6. ROIC - WACC (= -16.27)% |
| 7. RoE -20.31% |
| 8. Rev. Trend 91.11% |
| 9. EPS Trend 59.27% |
What is the price of SRPT shares?
Over the past week, the price has changed by +5.13%, over one month by +5.58%, over three months by +20.48% and over the past year by -82.07%.
Is SRPT a buy, sell or hold?
- Strong Buy: 14
- Buy: 8
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SRPT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20.6 | -6.8% |
| Analysts Target Price | 20.6 | -6.8% |
| ValueRay Target Price | 22.7 | 2.8% |
SRPT Fundamental Data Overview December 24, 2025
P/E Forward = 17.1233
P/S = 0.9217
P/B = 1.6852
P/EG = 159.25
Beta = 0.531
Revenue TTM = 2.41b USD
EBIT TTM = -230.4m USD
EBITDA TTM = -180.7m USD
Long Term Debt = 1.04b USD (from longTermDebt, last quarter)
Short Term Debt = 10.2m USD (from shortTermDebt, last quarter)
Debt = 1.25b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 637.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.62b USD (2.22b + Debt 1.25b - CCE 851.0m)
Interest Coverage Ratio = -10.58 (Ebit TTM -230.4m / Interest Expense TTM 21.8m)
FCF Yield = -14.73% (FCF TTM -386.4m / Enterprise Value 2.62b)
FCF Margin = -16.01% (FCF TTM -386.4m / Revenue TTM 2.41b)
Net Margin = -11.25% (Net Income TTM -271.5m / Revenue TTM 2.41b)
Gross Margin = 76.25% ((Revenue TTM 2.41b - Cost of Revenue TTM 573.2m) / Revenue TTM)
Gross Margin QoQ = 62.25% (prev 75.04%)
Tobins Q-Ratio = 0.75 (Enterprise Value 2.62b / Total Assets 3.49b)
Interest Expense / Debt = 0.61% (Interest Expense 7.57m / Debt 1.25b)
Taxrate = 7.27% (-14.1m / -194.0m)
NOPAT = -213.7m (EBIT -230.4m * (1 - 7.27%)) [loss with tax shield]
Current Ratio = 2.95 (Total Current Assets 2.72b / Total Current Liabilities 921.4m)
Debt / Equity = 0.95 (Debt 1.25b / totalStockholderEquity, last quarter 1.32b)
Debt / EBITDA = -3.53 (negative EBITDA) (Net Debt 637.1m / EBITDA -180.7m)
Debt / FCF = -1.65 (negative FCF - burning cash) (Net Debt 637.1m / FCF TTM -386.4m)
Total Stockholder Equity = 1.34b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.77% (Net Income -271.5m / Total Assets 3.49b)
RoE = -20.31% (Net Income TTM -271.5m / Total Stockholder Equity 1.34b)
RoCE = -9.71% (EBIT -230.4m / Capital Employed (Equity 1.34b + L.T.Debt 1.04b))
RoIC = -8.72% (negative operating profit) (NOPAT -213.7m / Invested Capital 2.45b)
WACC = 7.55% (E(2.22b)/V(3.47b) * Re(11.48%) + D(1.25b)/V(3.47b) * Rd(0.61%) * (1-Tc(0.07)))
Discount Rate = 11.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -2.57%
Fair Price DCF = unknown (Cash Flow -386.4m)
EPS Correlation: 59.27 | EPS CAGR: 6.87% | SUE: 0.46 | # QB: 0
Revenue Correlation: 91.11 | Revenue CAGR: 20.02% | SUE: 1.85 | # QB: 5
EPS next Quarter (2026-03-31): EPS=0.69 | Chg30d=-0.047 | Revisions Net=+0 | Analysts=6
EPS next Year (2026-12-31): EPS=2.80 | Chg30d=-0.381 | Revisions Net=+6 | Growth EPS=+237.6% | Growth Revenue=-25.1%
Additional Sources for SRPT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle